A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
A phase 2 trial of AK146D1 in advanced solid tumours, run by Akeso, now recruiting.
Overview
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer is a phase 2 interventional study registered as NCT07591090 by Akeso, with 200 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-09-01. Interventions recorded: AK146D1 for injection and AK112 Injection.
Similar pages
not linked directly; found by shared links- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.